Summary

A few days back I had reported that Glenmark by its positive number growth in these tough times has proved it self. Glenmark is relatively less well known company compared to to compatriots in the international investment scene, for this reason I had tagged it "Hidden Jewel of Indian Pharma. Sloane Robinson LLP has just reaffirmed my analysis by increasing their stake in Glenmark.  

Analysis

Sloane Robinson LLP has timed the invest quite well. Indian equities are relatively good value today than what they were during last year.

Glenmark's business is based on solid and practical business principles.

Glenmark is still good value with plenty of upward movement left.


This author consults with leading institutions through GLG

Engage this author or other Business of Medicine experts
 
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.